D-mannose suppresses HIF-1α mediated metabolic reprogramming in clear cell renal cell carcinoma
Authors:
Open Access
- 21 October 2025
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-11
Abstract
The inactivation mutation of VHL drives the progression of clear cell renal cell carcinoma (ccRCC), while the deletion of VHL leads to the failure of HIF-1/2α to degrade normally through the ubiquitin proteasome pathway. Notably, the abnormal accumulation of HIF-1/2α results in metabolic reprogramming and promotes the occurrence of tumors. Therefore, inhibition of metabolic reprogramming of ccRCC may be an effective treatment. In methodology, the viabilities of tumor cells were detected by cell counting kit-8 assay in vitro. The expression levels of related proteins were analyzed by western blotting assay, and the mRNA levels of genes were assessed by RT-qPCR assay. Glucose uptake, intracellular lactate and NADPH production were measured according to relevant instructions. Here, we found that D-mannose inhibits the proliferation of ccRCC in vitro. Mechanistically, D-mannose suppresses the transcription of HIF-1α downstream target genes, including GLUT1, LDHA, PDK1 and VEGF, by downregulating the protein level of HIF-1α in ccRCC cells. Furthermore, D-mannose reduces glucose uptake and intracellular lactate and NADPH production. To sum up, this study demonstrates that targeting HIF-1α by D-mannose to inhibit metabolic reprogramming is a promising strategy for ccRCC and complements a previously unknown role of D-mannose in cancer treatment.Keywords
This publication has 21 references indexed in Scilit:
- Improved therapy for clear cell renal cell carcinoma: beta-hydroxybutyrate and quercetin target hypoxia-induced angiogenesis and multidrug resistanceMolecular Biology Reports, 2024
- Targeting apoptosis and unfolded protein response: the impact of β-hydroxybutyrate in clear cell renal cell carcinoma under glucose-deprived conditionsMolecular Biology Reports, 2024
- Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinomaLaboratory Investigation, 2022
- HIF-1α Metabolic Pathways in Human Cancer2021
- Selective killing of cancer cells harboring mutant RAS by concomitant inhibition of NADPH oxidase and glutathione biosynthesisCell Death & Disease, 2021
- D-mannose suppresses macrophage IL-1β productionNature Communications, 2020
- Clear cell renal cell carcinoma ontogeny and mechanisms of lethalityNature Reviews Nephrology, 2020
- Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinomaOncogene, 2015
- Comprehensive molecular characterization of clear cell renal cell carcinomaNature, 2013
- HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progressionNature Reviews Cancer, 2011